-
Press ReleasesMEDIA INQUIRIES Media@BriiBio.com
-
Brii Biosciences Provides Corporate Update on Progress Against Strategic R&D Priorities
December 17, 2020
- Initiated clinical research of investigational monoclonal antibodies BRII-196 and BRII-198 in combination for the treatment of COVID-19 in collaboration with the NIH-NIAID
- Continues to rapidly advance the development of potential therapeutics for the mitigation of serious infectious disease threats by HBV, multi-drug resistant gram-negative bacteria, and HIV
- Continues to advance CNS programs with IND for BRII-296 planned for January 2021
- Expanded U.S. Leadership Team with Executive Appointments -
Brii Biosciences Appoints Rogers Luo, Ankang Li To Leadership Positions
September 18, 2020
- Rogers Yongqing Luo, B.M., MBA, President of Brii Bio and General Manager for Greater China, will lead acceleration of Brii Bio’s China strategy and expand the company’s capabilities in access and partnerships
- Ankang Li, Ph.D., J.D., CFA, Brii Bio’s Chief Financial Officer, will lead all financial and corporate development functions -
Tsinghua University, 3rd People’s Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19
March 31, 2020
- Multiple highly potent, neutralizing antibodies already identified from convalesced patients
- First-in-human trials planned for third quarter this year -
Brii Biosciences Provides Funding to Columbia University for Research on COVID-19 and Other Coronaviruses
March 11, 2020
- Brii Biosciences will provide funding and expertise in infectious disease treatment modalities for projects in development in Aaron Diamond AIDS Research Center and other Columbia Laboratories
